You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

GLIMEPIRIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Glimepiride patents expire, and when can generic versions of Glimepiride launch?

Glimepiride is a drug marketed by Accord Hlthcare, Actavis Labs Fl Inc, Aurobindo Pharma Ltd, Carlsbad, Chartwell Molecular, Dr Reddys Labs Ltd, Epic Pharma Llc, Hikma Pharms, Indoco Remedies, Micro Labs, Mylan, Norvium Bioscience, Prinston Inc, Ranbaxy, Ranbaxy Labs Ltd, Teva, and Watson Labs. and is included in seventeen NDAs.

The generic ingredient in GLIMEPIRIDE is glimepiride. There are sixteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the glimepiride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Glimepiride

A generic version of GLIMEPIRIDE was approved as glimepiride by CHARTWELL MOLECULAR on October 6th, 2005.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GLIMEPIRIDE?
  • What are the global sales for GLIMEPIRIDE?
  • What is Average Wholesale Price for GLIMEPIRIDE?
Drug patent expirations by year for GLIMEPIRIDE
Drug Prices for GLIMEPIRIDE

See drug prices for GLIMEPIRIDE

Drug Sales Revenue Trends for GLIMEPIRIDE

See drug sales revenues for GLIMEPIRIDE

Recent Clinical Trials for GLIMEPIRIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jiangsu Province Geriatric InstitutePhase 4
Peking University People's HospitalPhase 4
Peking University First HospitalPhase 4

See all GLIMEPIRIDE clinical trials

Pharmacology for GLIMEPIRIDE
Drug ClassSulfonylurea

US Patents and Regulatory Information for GLIMEPIRIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Prinston Inc GLIMEPIRIDE glimepiride TABLET;ORAL 077370-002 Dec 23, 2005 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Micro Labs GLIMEPIRIDE glimepiride TABLET;ORAL 091220-005 Jun 29, 2012 RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ranbaxy Labs Ltd GLIMEPIRIDE glimepiride TABLET;ORAL 076875-004 Oct 6, 2005 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

GLIMEPIRIDE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Glimepiride

Introduction to Glimepiride

Glimepiride, a sulfonylurea, is a prescription drug used to treat type 2 diabetes. It is available in both brand-name (Amaryl) and generic forms. Understanding the market dynamics and financial trajectory of glimepiride is crucial for pharmaceutical companies, investors, and healthcare providers.

Market Size and Growth Projections

The glimepiride tablet market has experienced rapid and substantial growth in recent years. Here are some key projections:

  • The market is expected to continue its significant expansion from 2023 to 2031, with forecasts indicating robust growth rates throughout the forecast period[1][3][4].
  • The global glimepiride market size was valued at USD xx billion in 2023 and is anticipated to reach USD xx billion by 2031, exhibiting a notable compound annual growth rate (CAGR)[3][4].

Market Segmentation

The glimepiride market is segmented based on several factors:

  • Type: The market is categorized into different packaging types, such as 3 blisters/box and 10 blisters/box[1][3].
  • Application: The drug is used for treating people with mild diabetes and those with severe diabetes[1][3].
  • Geographical Regions: The market is analyzed across North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa[1][3][4].

Drivers of Market Growth

Several factors are driving the growth of the glimepiride market:

  • Increasing Prevalence of Diabetes: The rising incidence of type 2 diabetes globally is a significant driver, as more patients require effective treatments like glimepiride[4].
  • Cost-Effectiveness: Glimepiride, being a generic drug, is generally more affordable than brand-name medications, making it a preferred choice for many patients[2][5].
  • Market Penetration: The drug's widespread use and acceptance in various regions contribute to its market growth[1][3].

Restraints and Challenges

Despite the positive growth trajectory, there are some challenges:

  • Competition from Other Diabetes Treatments: The diabetes treatment market is highly competitive, with various other medications and therapies available, which can impact glimepiride's market share[4].
  • Regulatory Hurdles: Changes in regulatory policies and stringent approval processes can affect the market dynamics[4].

Financial Factors Affecting Glimepiride Costs

The cost of glimepiride can vary based on several financial factors:

  • Dosage and Treatment Plan: Higher strengths of glimepiride (e.g., 4 mg vs. 2 mg) may cost more than lower strengths[2][5].
  • Insurance Coverage: Patients with health insurance may pay less compared to those without insurance. The specific plan benefits and prior authorization requirements also play a role[2][5].
  • Pharmacy and Supply Chain: The cost can differ depending on the pharmacy used and whether the medication is obtained through a mail-order pharmacy or in-person[2][5].

Cost-Saving Strategies

For patients looking to reduce their costs, several strategies can be employed:

  • 90-Day Supply: Obtaining a 90-day supply of glimepiride, if approved by the insurance company, can reduce the number of trips to the pharmacy and lower costs[2].
  • Mail-Order Pharmacies: Using mail-order pharmacies can help lower costs and provide the convenience of home delivery[2].
  • Financial Assistance Programs: Various websites and programs offer savings cards and other financial assistance to help patients afford glimepiride[2].

Regional Market Analysis

The glimepiride market is analyzed across several major regions:

  • North America: This region is expected to contribute significantly to the global market due to high healthcare spending and a large diabetic population[1][3][4].
  • Europe: Europe also plays a crucial role, with a well-established healthcare system and a significant number of diabetes patients[1][3][4].
  • Asia-Pacific: This region is anticipated to experience rapid growth due to the increasing prevalence of diabetes and improving healthcare infrastructure[1][3][4].

Competitive Landscape

The glimepiride market is competitive, with several key players:

  • Physicians Total Care Inc.
  • Sandoz
  • Apotex
  • GlaxoSmithKline Inc.
  • Perrigo
  • CorePharma LLC

These companies are focusing on strategies to strengthen their product portfolios and expand their market presence[4].

Key Takeaways

  • The glimepiride market is poised for significant growth from 2023 to 2031.
  • The market is driven by the increasing prevalence of diabetes and the cost-effectiveness of glimepiride.
  • Financial factors such as dosage, insurance coverage, and pharmacy choice significantly affect the cost of glimepiride.
  • Cost-saving strategies like obtaining a 90-day supply and using mail-order pharmacies can help reduce costs.
  • The market is competitive, with several key players vying for market share.

FAQs

1. What are the main factors affecting the cost of glimepiride? The cost of glimepiride is influenced by factors such as dosage, treatment plan, insurance coverage, and the pharmacy used[2][5].

2. How does the cost of glimepiride vary with and without insurance? Without insurance, the cost of glimepiride is generally higher. With insurance, the cost depends on specific plan benefits and prior authorization requirements[2][5].

3. What are some cost-saving strategies for glimepiride? Patients can save costs by obtaining a 90-day supply, using mail-order pharmacies, and taking advantage of financial assistance programs[2].

4. Which regions are expected to contribute significantly to the glimepiride market? North America, Europe, and the Asia-Pacific region are anticipated to be major contributors to the global glimepiride market[1][3][4].

5. Who are the key players in the glimepiride market? Key players include Physicians Total Care Inc., Sandoz, Apotex, GlaxoSmithKline Inc., Perrigo, and CorePharma LLC[4].

Sources

  1. Market Research Intellect - Global Glimepiride Tablet Market Size, Trends and Projections
  2. Healthline - Glimepiride (Amaryl) Cost and Financial Assistance
  3. Market Research Intellect - Global Glimepiride Tablet Market Size, Scope And Forecast Report
  4. Cognitive Market Research - Glimepiride Market Report 2024 (Global Edition)
  5. Medical News Today - Glimepiride cost 2024: Coupons and more

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.